Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Qiagen NV (NASDAQ:QGEN)

27.98
Delayed Data
As of Jul 31
 -0.21 / -0.74%
Today’s Change
20.73
Today|||52-Week Range
28.31
+19.27%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$6.6B

Company Description

QIAGEN NV is engaged in the provision of sample and assay technologies. Its products include instruments and consumables. The company's Sample technologies are used to isolate DNA (deoxyribonucleic acid), RNA (ribonucleic acid) and proteins from any biological sample, such as blood or tissue as well as plants and other samples that contain biological materials. Its Assay technologies are used to amplify, enrich and provide results for analysis, such as the DNA of a virus or a mutation of a gene contained in a cancer cell, and these are supported by a portfolio of industry-leading bioinformatics solutions. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, Netherlands.

Contact Information

QIAGEN NV
Spoorstraat 50
Venlo Limburg 5911 KJ
P:(177) 320-8400
Investor Relations:
4921032911711

Employees

Shareholders

Mutual fund holders44.46%
Other institutional22.12%
Individual stakeholders--

Top Executives

Peer M. SchatzChief Executive Officer & Co-Managing Director
Roland SackersManaging Director & Chief Financial Officer
Douglas LiuSenior Vice President-Global Operations
Tadd S. LazarusChief Medical Officer
Ulrich SchriekSenior Vice President-Business Development